good morning name crystal conference operator morning time would like welcome everyone danaher corporation second quarter earn result conference call line place mute prevent background noise speaker remark question answer session operator instruction turn call vice president investor relation begin conference vice president investor relation thank crystal good morning everyone thank join call today president chief executive officer executive vice president chief financial officer like point earn release slide presentation supplement today call reconciliation information require regulation relate financial measure provide call available investor section website danaher head quarterly earn audio portion call archive investor section website later today head event presentation remain archive next quarterly call replay call also available presentation describe certain significant factor impact year year performance supplemental material describe additional factor impact year year performance unless otherwise note reference remark supplemental material company specific financial metric refer result continue operation relate second quarter reference period period increase decrease financial metric year year also describe certain product device application submit pending regulatory certain regulatory approval available certain market call make forward look statement within mean federal security include statement regard event development believe anticipate occur future forward look statement subject number risk uncertainty include forth file actual result differ materially forward look statement make today forward look statement speak date make assume obligation update forward look statement except require result size acquisition impact danaher overall core revenue growth profile present core revenue basis include sale reference core revenue growth exclude sale calculation period period sale growth like turn call president chief executive thank good morning everyone appreciate join call today please strong start year another terrific result second quarter broad base strength across portfolio help deliver core revenue growth adjust earn share growth outstanding free cash flow generation round performance testament position portfolio exceptional commit lead execute danaher business system every second quarter continue strengthen competitive advantage significant high impact organic growth investment enhance portfolio strategic growth accelerate acquisition prioritize innovation across danaher increase production capability believe contribute market share gain several business also announce pending acquisition expand presence grow important frontier genomic medicine together believe combination lead portfolio drive execution differentiate danaher today provide strong foundation sustainable long term outperformance turn second quarter result sale billion deliver core revenue growth strong contribution three report segment geographically high growth market grow nearly develop market revenue three largest market north western quarter gross profit margin increase basis point primarily higher sale volume favorable impact higher margin product impact prior year purchase account adjustment relate acquisition repeat operate profit margin increase include basis point core operate margin expansion primarily result higher gross margin continue lower operate expense travel relate remain pandemic level adjust dilute earn common share compare generate billion free cash flow quarter year year announce intention acquire producer high quality plasmid protein serve academic biotechnology pharmaceutical customer addition expand capability important field genomic medicine accelerate adoption gene cell therapy vaccine gene edit technology anticipate accretive danaher multiple level expect business generate million revenue annual revenue growth strong margin profile look forward welcome incredibly talented innovative danaher transaction close addition announce acquisition also accelerate several organic growth investment across portfolio core value danaher innovation define future make significant commitment toward research development effort increase research development spend year year bring impactful solution customer launch high resolution accurate mass spectrometry system enable scientist identify characterize quantify molecule previously level help advance development biotherapeutics precision diagnostics diagnostics recently introduce compact automation solution design small size laboratory reduce manual step typically require sample preparation great example continue invest growth across danaher support customer enhance competitive advantage innovation additionally make substantial investment expand capacity across process business near term investment support exist customer demand drive market meaningful share gain equally important support long term growth business tremendous runway ahead give underlie structural growth driver market serve expect total capital expenditure across danaher approximately billion continue invest supportive customer need today future believe strategic combination organic inorganic investment across portfolio reinforce competitive advantage accelerate growth trajectory forward detail quarterly result across segment life science report revenue increase core revenue growth broad base major business platform deliver better core growth continue strong demand bioprocessing solution combine core revenue growth biotech relate bioprocessing business double digit robust customer activity order rate relate vaccine therapeutic revenue consistent first quarter exceed billion first month year remiss take moment reflect fantastic first year part danaher establish company brand name associate make substantial progress transition danaher maintain world class support customer significantly ramp production capacity grow revenue announce acquisition talk strategic value creation opportunity excite welcome talented engage danaher think fair exceed expectation every really testament embrace danaher danaher business system continue execute exceptionally support customer move diagnostics report revenue core revenue grow lead core growth diagnostics grow patient volume clinical diagnostic activity approach pandemic level around world growth outside respiratory test lead sexual health hospital acquire infection assay particularly among newly acquire customer respiratory test believe continue gain market share expand manufacture capacity enable produce ship approximately million cartridge quarter expect test account approximately shipment combination test represent approximately broad base performance across drive thoughtful base expansion last month evidence significant value provide clinician unique combination accurate quality result best class easy workflow point care move environmental apply solution segment report revenue grow core revenue revenue growth accelerate across platform water quality high single digit product identification approximately quarter water quality business demand analytical chemistry consumables drive improve activity across municipal chemical food beverage market equipment order rate accelerate customer back begin invest larger project product identification teen package color management business quarter acceleration reflect broad base recovery growth across major geography market backdrop quarter spend time trend geographically across market look condition around world major region country broadly return approach normal operation reflect strong result across mindful emerge variant drive outbreak take action help minimize potential impact respective business point material impact recent variant selective lockdown positive momentum across business order growth trend revenue growth market largely recover growth rate pandemic level customer adopt environment person commercial activity continue rebound spend time site customer trend expect continue move year across life science healthy demand market lead biopharma pace customer activity remain elevate biotech fund level robust number lifesaving biologic genomic base therapy development production continue rise augment work around vaccine therapeutic today monoclonal antibody base therapy development globally increase year also gene therapy candidate development today fold increase last several year technology mature therapy gain regulatory approval give many candidate still early stage research expect growth rate market remain strong many year come addition growth biologics genomic base medicine significant demand relate vaccine therapeutic market development today give interest customer look address emerge variant increase global supply evolve vaccination guideline globally expect durable growth segment biopharma market foreseeable future current pace vaccination clear vaccine demand continue next year expect recognize billion relate vaccine therapeutic revenue anticipate enter approximately billion relate backlog assumption include potential contribution booster expansion availability population year level uncertainty around scenario give grow number drug develop increase scientific sophistication require discover manufacture complex therapy customer look partner vendor reliably supply solution challenge problem move production scale comprehensive process portfolio scientific expertise position confident proactive investment innovation capacity help meet grow customer demand future clinical diagnostics market patient volume near pandemic level major region patient return wellness check routine screen elective procedure molecular diagnostics respiratory test volume decline persistent demand test point care outside make approximately half revenue continue strong demand test vaccination rate emerge variant drive outbreak mention earlier ship approximately million respiratory test second quarter million ship first quarter expect ship approximately million test look ahead assumption endemic disease believe point care molecular respiratory test market expand significantly prior pandemic give lead position around speed accuracy ease workflow advantage believe continue gain market share combination market share gain expansion lead global base broadest molecular diagnostic test menu market create significant opportunity ahead broader utilization demand point care molecular test solution move apply market continuation steady improvement first half year customer activity accelerate line broader economic activity healthy order rate consumables increase investment equipment across municipal market globally consumables demand remain solid customer continue test treat water instrument orient project activity accelerate improve fund environment look ahead expectation third quarter full year expect deliver third quarter core revenue growth high teen range anticipate high single digit core revenue growth base business high single digit core growth contribution relate revenue tailwind additionally expect generate operate profit fall approximately third quarter remainder full year expect deliver approximately core revenue growth anticipate relate revenue tailwind approximately contribution core revenue growth rate base business expect core revenue full year increase prior expectation high single digit wrap great start year meaningful opportunity across danaher build upon outstanding performance second quarter result reiterate power portfolio exceptional unique combination differentiate danaher today provide strong foundation sustainable long term outperformance back vice president investor conclude formal comment ready question